Refractory intracranial hypertension in traumatic brain injury: Proposal for a novel score to assess the safety of lumbar cerebrospinal fluid drainage.
Marlies Bauer, Florian Sohm, Claudius Thomé...
https://pubmed.ncbi.nlm.nih.gov/29184716/Actively Recruiting
Led by Brain Trauma Foundation · Updated on 2026-04-22
30
Participants Needed
6
Research Sites
2 weeks
Total Duration
Researchers are evaluating the safety and feasibility of external lumbar drainage ELD as an additional treatment to reduce brain pressure in patients with severe traumatic brain injury TBI. This phase 1 randomized controlled trial compares usual care alone to usual care plus ELD in patients who have specific brain imaging findings, such as patent basal cisterns and a midline shift less than 5mm. The study aims to determine whether ELD can be safely performed without increasing risks like neurological worsening or brain herniation. Participants will be randomly assigned to one of three groups early ELD at 15 mmHg if intracranial pressure ICP is not raised, ELD at 20 mmHg if ICP remains above 20 mmHg despite other treatments, or usual treatment alone following established guidelines. The ELD procedure involves controlled drainage of cerebrospinal fluid with a maximum volume of 10 ml per hour. All patients receive standard care, with the addition of ELD in the intervention groups, and no treatments are withheld. During the study, participants will undergo regular neurological monitoring including automated pupillometry every hour and Glasgow Coma Scale assessments. Safety monitoring is intensified around ELD placement with pupillometry every 15 minutes for the first hour. Researchers will measure the safety and feasibility of ELD over 10 days and investigate how well pupillometry predicts safety. The trial includes follow-up for neurological worsening events, intracranial pressure changes, and adverse events, with safety oversight by an expert board.
CONDITIONS
External Lumbar Drainage to Reduce ICP in Severe TBI: a Phase 1 Clinical Trial
C
Carlos Morales, MPH
H
Halinder S Mangat, MD, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Brain Trauma Foundation
Lead Sponsor
Uniformed Services University of the Health Sciences
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | ELD started prophylactically within 24h of injury | ELD initiated as treatment for raised ICP | Standard care per SIBICC consensus recommendations |
|---|---|---|---|
| What it is | Prophylactic insertion of an external lumbar drainage catheter within 24 hours of severe traumatic brain injury, set at the protocol-specific drainage threshold and volume limits. | External lumbar drainage catheter initiated as a therapeutic procedure in response to elevated intracranial pressure after severe TBI, using the same device and drainage settings as in the prophylactic arm. | Standard guideline-based management for intracranial hypertension after severe TBI focuses on stepwise measures like hyperosmolar therapy, sedation, and decompressive surgery when indicated. Lumbar drainage is not recommended as a frontline practice under current SIBICC consensus. |
| Role in trial | Tested as an early/preventive intervention to reduce risk of intracranial hypertension after severe traumatic brain injury. | Used as a therapeutic response to documented intracranial hypertension during the trial period in eligible severe TBI patients. | Stepwise management approach for intracranial hypertension. ELD rarely plays any role, reserved only for select refractory cases if other measures fail as per expert review. |
| Primary use | Preventative reduction of intracranial pressure by proactively draining cerebrospinal fluid soon after injury. | Treatment of established intracranial hypertension via cerebrospinal fluid drainage during the acute phase after injury. | Control of intracranial pressure through medical and surgical standard options: osmotic agents, sedation, controlled ventilation, and surgical decompression. |
| How it is given or performed | Lumbar drainage catheter is placed early, managed to target ICP at 15-20 mmHg, with drainage limited to 10ml/hour, supervised closely for adverse events. | Catheter placement occurs after confirmation of intracranial hypertension, drainage protocol mirrors prophylactic arm and includes close monitoring of ICP and potential complications. | Current-care pathway includes repeated medical interventions such as hyperosmolar agents, therapeutic sedation, mechanical ventilation, and potential surgical decompression, performed according to guideline escalation. Lumbar drainage is not routine. |
| Evidence status | Safety and feasibility are the primary trial outcomes. Published literature supports potential for ICP reduction but indicates safety risks exist, especially for early use. Robust efficacy data is not yet established. | Prior literature and meta-analyses indicate lumbar drainage can reduce intracranial pressure in severe TBI, but there are persistent safety concerns and inconsistent outcome benefits. Robust efficacy in the randomized context is still under investigation. | Established efficacy for stepwise medical and surgical management in reducing ICP, validated by consensus guideline supported by broad clinical evidence. Lumbar drainage is not part of the standard regimen due to safety and benefit concerns. |
| Important limitations | Safety profile not yet determined; early lumbar drainage carries risk of spinal cord injury, infection, and worsening cerebral edema. Clinical benefit for early use is uncertain until sufficient data is collected. | Lumbar drainage as a therapeutic intervention may lead to complications such as infection, herniation, and neurological deterioration. Its overall benefit in the acute treatment setting is not conclusively proven and awaits further rigorous evaluation. | Standard guideline-based management depends on availability of advanced medical care and may not address intracranial hypertension in all settings. Lumbar drainage is avoided due to risk of adverse outcomes; guideline limitations relate to resource variability. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 days
Participants receive external lumbar drainage (ELD) at 15 or 20 mmHg with a maximum drainage of 10 ml/hour as an adjunct to usual treatments to lower intracranial pressure, or usual treatment alone as per the study group assignment.
Continuous monitoring including automated pupillometry every 15 minutes for 1 hour after ELD placement, then hourly; hourly Glasgow Coma Scale checks and routine ICU protocols
Duration - Up to 10 days
Participants are monitored for safety and feasibility outcomes related to the treatment, including neuro-worsening events and ICP burden.
Monitoring visits as part of ICU care
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Marlies Bauer, Florian Sohm, Claudius Thomé...
https://pubmed.ncbi.nlm.nih.gov/29184716/Ali Murad, Samer Ghostine, Austin R T Colohan
https://pubmed.ncbi.nlm.nih.gov/22154151/E E Ginalis, L L Fernández, J P Ávila...
https://pubmed.ncbi.nlm.nih.gov/34051245/Jetan Badhiwala, Angela Lumba-Brown, Gregory W J Hawryluk...
https://pubmed.ncbi.nlm.nih.gov/34171100/Josep M Abadal-Centellas, Juan A Llompart-Pou, Javier Homar-Ramírez...
https://pubmed.ncbi.nlm.nih.gov/17297313/J A Llompart-Pou, J M Abadal, J Pérez-Bárcena...
https://pubmed.ncbi.nlm.nih.gov/21375095/Jochen Tuettenberg, Marcus Czabanka, Peter Horn...
https://pubmed.ncbi.nlm.nih.gov/19249925/Gregory W J Hawryluk, Sergio Aguilera, Andras Buki...
https://pubmed.ncbi.nlm.nih.gov/31659383/Brain Trauma Foundation
Lead Sponsor
Uniformed Services University of the Health Sciences
Collaborating Sponsor